Ratings Hikal Limited NSE India S.E.

Equities

Market Closed - NSE India S.E. Other stock markets 07:43:48 2024-05-03 am EDT			5-day change	1st Jan Change
297.4 ^INR	-1.90%		-3.63%	-2.14%

Apr. 08	Hikal Limited agreed to acquire 5.73% stake in FPEL Ujwal Private Limited for INR 41.2 million.	CI
Apr. 01	Hikal Limited Announces Completion of Tenure of Non-Executive, Independent Directors	CI

On the basis of various fundamental qualitative criteria, the company appears to be particularly poorly ranked from a medium and long-term investment perspective.

Analysts covering this company mostly recommend stock overweighting or purchase.
Over the past twelve months, analysts' opinions have been strongly revised upwards.

With an expected P/E ratio at 54.08 and 35.41 respectively for both the current and next fiscal years, the company operates with high earnings multiples.
The company appears highly valued given the size of its balance sheet.
The firm pays small or no dividend to shareholders. For that reason, it is not a yield company.
For the last twelve months, sales expectations have been significantly downgraded, which means that less important sales volumes are expected for the current fiscal year over the previous period.
For the last four months, the sales outlook for the coming years has been revised downwards. No recovery of the group's activities is yet foreseen.
For the last 12 months, analysts have been regularly downgrading their EPS expectations. Analysts predict worse results for the company against their predictions a year ago.
For the last four months, EPS estimates made by Standard & Poor's analysts have been revised downwards.

	1st Jan change	Capi.	ESG Refinitiv
HIKAL LIMITED	-2.14%	447M	-
ELI LILLY AND COMPANY	+26.08%	681B	C+
NOVO NORDISK A/S	+21.85%	556B	B
JOHNSON & JOHNSON	-4.77%	361B	C+
MERCK & CO., INC.	+16.97%	325B	B-
ABBVIE INC.	+5.69%	285B	C+
ASTRAZENECA PLC	+13.68%	235B	B+
NOVARTIS AG	+3.65%	199B	B-
ROCHE HOLDING AG	-11.12%	189B	A+
PFIZER, INC.	-3.40%	157B	C+

Investor Rating

Trading Rating

ESG Refinitiv

Sales growth

Earnings Growth

EBITDA / Sales

Profitability

Finances

P/E ratio

EV / Sales

Price to Book

Price to Free Cash Flow

Yield

1 year Revenue revision

4 months Revenue revision

7 days Revenue revision

1 year EPS revision

4 months EPS revision

Analyst Opinion

Potential Price Target

4m Target Price Revision

4m Revision of opinion

12m Revision of opinion

Analyst Coverage

Divergence of Estimates

Divergence of analysts' opinions

Divergence of Target Price

Earnings quality